p53 oncoprotein as a prognostic indicator in patients with breast cancer

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 507-511

  Molina, R ^a   Segui, M A ^b   Climent, M A ^c   Bellmunt, J ^d   Albanelll, J ^d   Fernandez, M ^e   Filella, X ^a   Jo, J ^a   Gimenez, N ^a   Iglesias, E ^f   Miralles, M ^f   Alonso, C ^g   Peiro, G ^g   Perez Picanol E ^h   Ballesta, A M ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b España   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e Hosp Nuestra Senora Pino Gran C   (Spain)

^f HOSPITAL ARNAU DE VILANOVA   (Spain)

^g Hospital de la Sta Cruz y Sant Pau ^*  (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Breast cancer; Oncogenes; Oncoproteins; p53; Prognosis

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOMAL LOCALIZATION; CHROMOSOME 17; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE LOCATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

BREAST NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 15444353870     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
2. Porter PL, Gown AN, Kramp SG and Coltrera MD: WidesRread p53 overexpression in human malignant tumors. Am J Pathol 140: 145-53, 1992.
3. Levine AJ, Momand J and Finlay CA: The p53 tumor suppresor gene. Nature 351: 453-6, 1991.
4. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71: 543-6, 1992.
5. Finlay CA, Hinds PW and Levine AJ: The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083-90, 1989.
6. Cattoretti G, Rilke F, Andreola S, D'Amato L and Delia D: p53 expression in breast cancer. Int J Cancer 41: 178-83, 1988.
7. Iggo R, Gatter K, Bartek J, Lane D and Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-81, 1990.
8. Molina R, Filella X, Segui MA, Climent MA, Perez-Picanol E, Alonso C, Jo J, Ojeda B, Tandon AK and Ballesta AM: Oncogenic proteins and prognostic correlations in breast cancer. In Vivo 7: 585-90, 1993.
9. Horak E, Smith K, Bromley L, Le Jeune S, Greenall M, Lane D and Harris AL: Mutant p53, EOF receptor and c-erbB-2 expression in human breast cancer. Oncogene 6: 2277-83, 1991.
10. Allred DC, Clark GM, Elledge RI, Fuqua SA, Brown RW, Chamness GC, Osborne CK and McGuire WL: Accumulation of mutant p53 is associated with increased proliferation and poor clinical outcome in node-negative breast cancer. JNCI 85: 176-7, 1993.
11. Thor AD; Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC and Mayall BH: Increased accumulation of the p53 suppressor gene product is an independent prognostic variable for breast cancer. JNCI 84: 845-55, 1992.
12. International Union Against Cancer (UICC): TNM classification of malignant tumours. Hermanek P, Soben LH eds., 4 ed. Berlin: Springer Verlag, 1987.
13. Lane DP and Crawford LV: T antigen is bound to a host protein in SV-40transformed cells. Nature 278: 261-3, 1979.
14. Gazdar AF: Molecular markers for the diagnosis and prognosis of lung cancer. Cancer 69: 1592-9, 1992.
15. Scott N, Segar P, Steward J, Blair GE, Dixon MF and Quirke P: p53 in colorectal cancer:clinicopathological correlation and prognostic significance. Br J Cancer 63: 317-9, 1991.
16. Koeffler HP, Miller C, Nicolson MA, Raynard J and Bosselman RA: Increased expression of p53 protein in human leukemia cells. Proc Natl Acad Sci USA 83: 4035-9, 1986.
17. Rogel A, Poliker M, Webb CG and Oren M: p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 5: 2851-5, 1985.
18. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T and Hirohashi S: Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorhisru analysis. Cancer Res 57: 3056-8, 1991.
19. Casson AG, McCuaig S, Craig 1, Ayed A, Inculet R, Kerkvliet N and O Malley F: Prognostic value and clinicopathological correlation of p53 gene mutations and nuclear DNA content in human lung cancer: A prospective study. J Sur Oncol 56: 13-20, 1994.
20. Davidoff AM, Kerns B-JM, Iglehart JD and Marks JR: Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 51: 2605-10, 1991.
21. Walker RA, Dearing SJ, Lande DP and Varley JM: expression of p53-protein in infiltrating and in situ breast carcinomas. J Pathol 165: 203-11, 1991.
22. Varley JM, Brammar WJ, Lane DP, Swallow JE, Dolan C and Walker RA: Loss of chromosome 17p13 sequences and mutation of p53 in human breast carci nomas. Oncogene 6: 413-21, 1991.
23. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LCh, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. JNC 184: 845-5, 1992.
24. Morkve O and Laerum OD: Flow citometric measurement of p53 protein expression and DNA content in paraffin-embedded tssue from bronchial carcinomas. Citometry 12: 438-44, 1991.
25. Davidoff AM, Kerns BJM, Iglehart JD, Marks JR: Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 51: 2605-10, 1991.
26. Runnebaum IB, Nagarajan M, Bowman M, Soto D and Sukumar S: Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 88: 10657-61, 1991.
27. McGuire WL: Adjuvant therapy of node-negative breast cancer. N Engl J Med 320: 525-527, 1989.